Health care products maker Abbott Laboratories (NYSE: ABT) received US Food and Drug Administration approval to market its new glucose monitoring system for the nearly 26 million US diabetics who take insulin. The company said the device would be available in the US “in the coming months.”
Shares are up 2.45% at $57.64, after posting a new 52-week high of $57.66 earlier.
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
Our top personal finance-related articles today. Your wallet will thank you later.
Top Gaining Stocks
Top Losing Stocks